Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 9/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14410858 | 1.00 | PDE10A (0.49) | PDE10ACNR2APEX1CXCR6ROCK2 | |
| SCHEMBL5456328 | 0.96 | PDE10A (0.49) | PDE10ACNR2APEX1CXCR6ROCK2 | |
| SCHEMBL14412137 | 0.92 | PDE10A (0.48) | PDE10ACNR2ROCK2ROCK1 | |
| SCHEMBL14412205 | 0.92 | PDE10A (0.46) | PDE10ACNR2CXCR6 | |
| SCHEMBL5442810 | 0.92 | CNR2 (0.45) | PDE10ACNR2 | |
| SCHEMBL14411346 | 0.92 | CNR2 (0.45) | PDE10ACNR2 | |
| SCHEMBL14410860 | 0.92 | CNR2 (0.45) | PDE10ACNR2 | |
| SCHEMBL14412127 | 0.91 | PDE10A (0.44) | PDE10ACNR2APEX1 | |
| SCHEMBL5440772 | 0.90 | PDE10A (0.48) | PDE10ACNR2ROCK2ROCK1 | |
| SCHEMBL5469681 | 0.90 | CNR2 (0.44) | PDE10ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | PDE10A 514/4885CNR2 106/4885APEX1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.